The Revista Mexicana de Neurociencia, published by the ACAD MEXICANA NEUROLOGIA, serves as a pivotal platform for the dissemination of research within the field of neurology and neuroscience. Although it was active from 2008 to 2014 and is no longer covered in Scopus, the journal still holds a significant place in the academic community, addressing critical topics relevant to both clinical and experimental neurology. With an emphasis on advancing knowledge in neuropsychology and public health, this journal targets researchers, professionals, and students alike, fostering an interdisciplinary dialogue that can enhance the understanding of neurological conditions within Mexico and beyond. As it stands, the journal is not open access, which may present challenges for accessibility, yet its affiliation with recognized academic standards underlines its commitment to quality research. This platform once provided insights that can inform practice and stimulate innovative approaches in the management of neurological disorders, underscoring its importance in the evolving landscape of neuroscience.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.

Epilepsy & Behavior Reports, a distinguished journal published by ELSEVIER SCIENCE INC, specializes in the latest research and developments in the field of epilepsy and related behavioral conditions. Since its inception in 2019 as a fully Open Access journal, it has carved a niche for itself within the scientific community, providing an essential platform for researchers and clinicians focused on behavioral neuroscience and neurology. The journal's commitment to disseminating high-quality research is reflected in its current rankings within Scopus, placing it within the Q3 category for Behavioral Neuroscience and Clinical Neurology, underscoring its relevance to emerging trends in these fields. Located in the heart of New York, the journal strives to foster collaboration and innovation, making it a vital resource for academics, practitioners, and students eager to advance their understanding of epilepsy and its behavioral implications. The convergence of expertise and research in Epilepsy & Behavior Reports promises to illuminate crucial aspects of neurological health, driving forward the discourse that shapes future treatment and understanding of epilepsy.

ACTA NEUROPSYCHIATRICA is a distinguished journal published by Cambridge University Press, covering essential research across the fields of psychiatry and neuroscience. Since its inception in 1989, it has become a pivotal resource for researchers and clinicians, providing a platform for the latest advancements and insights in biological psychiatry. With an impressive Scopus rank of #66 out of 567 in the Psychiatry and Mental Health category, and #10 out of 51 in Biological Psychiatry, the journal is recognized for its significant contributions to the field, boasting an 88th percentile ranking in overall impact. Although it operates under a traditional access model, the journal remains committed to disseminating high-quality research that addresses critical issues in mental health. Whether you are a professional seeking the latest findings or a student aiming to deepen your knowledge, ACTA NEUROPSYCHIATRICA is an indispensable resource for cutting-edge developments that shape our understanding of the human mind.

Schizophrenia Research is a premier academic journal focused on innovative research within the domain of psychiatry and mental health, published by Elsevier. With its ISSN 0920-9964 and E-ISSN 1573-2509, the journal has established a strong presence since its inception in 1988, evolving to publish cutting-edge findings up to 2024. Positioned in Q1 in Psychiatry and Mental Health and Q2 in Biological Psychiatry, it ranks impressively in the 83rd percentile among its peers, according to Scopus, ranking #93/567 in the field of Medicine, and #12/51 in Neuroscience. This journal serves as a vital platform for the dissemination of significant scientific advancements and theoretical insights into schizophrenia, fostering a deeper understanding of mental illnesses. Although it operates on a subscription basis, its critical role in informing both ongoing research and clinical practices cannot be overstated, making it an essential resource for researchers, clinicians, and students alike. Join a global community dedicated to improving mental health outcomes and advancing the study of schizophrenia through this reputable publication.

Schizophrenia Research and Treatment, an esteemed journal published by HINDAWI LTD, serves as a pivotal open-access platform for innovative research in the fields of Neurology and Psychiatry. With an ISSN of 2090-2085 and E-ISSN of 2090-2093, this journal has established itself as a significant resource for scholars and practitioners since its inception in 2011, consistently contributing to the understanding and treatment of schizophrenia and related mental health issues. Based in Egypt and reaching a global audience, Schizophrenia Research and Treatment is classified in the 2023 Q2 category for both Neurology (Clinical) and Psychiatry and Mental Health, reflecting its importance and relevance in these disciplines. Notably, the journal ranks in the 61st percentile for Psychiatry and Mental Health and the 58th percentile for Clinical Neurology, indicating its solid reputation among peers. By disseminating critical findings and fostering dialogue among researchers, professionals, and students, this journal plays a crucial role in advancing the treatment and management of schizophrenia, ultimately benefiting patients and healthcare systems worldwide.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, published by the CMA-Canadian Medical Association, serves as a pivotal platform for disseminating cutting-edge research in the fields of psychiatry and neuroscience. This esteemed journal, indexed with the ISSN 1180-4882 and E-ISSN 1488-2434, focuses on advancing our understanding of mental health through meticulous peer-reviewed articles, reviews, and clinical studies. With an impressive impact within the research community, it has achieved notable rankings, including Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health, as well as Q2 in Biological Psychiatry as of 2023. The journal fosters critical dialogue among scholars and practitioners by offering insights into the complexities of brain function and mental disorders, making it a fundamental resource for healthcare professionals, researchers, and students alike. Although it operates under a subscription model, its rich content continues to inform and influence the advancement of mental health science, affirming its role in bridging the gap between research and clinical practice.

European Archives of Psychiatry and Clinical Neuroscience is a prominent peer-reviewed journal published by Springer Heidelberg, focusing on the interdisciplinary aspects of psychiatry and clinical neuroscience. With an ISSN of 0940-1334 and an E-ISSN of 1433-8491, this journal provides a rigorous platform for innovative research spanning biological psychiatry, pharmacology, and various aspects of mental health. The journal boasts a distinguished impact factor that places it in the Q2 category for Biological Psychiatry and Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health as of 2023, reflecting its significant contribution to the field. Additionally, its Scopus rankings highlight its esteemed position among the top journals, particularly in Medicine and Neuroscience disciplines. Readers can access a wealth of valuable research articles, case studies, and reviews, crucial for advancing understanding and treatment within these vital fields. Initially converged in 1990, the journal continues to evolve and support scholarly dialogue until 2024 and beyond, making it an essential resource for researchers, clinicians, and students alike.

Ideggyogyaszati Szemle-Clinical Neuroscience, an esteemed publication under the auspices of LITERATURA MEDICA, serves as a pivotal platform in the field of neurology and clinical neuroscience. Established in Hungary, this journal has been committed to advancing the understanding of neurological disorders and treatments since its inception. With its ISSN 0019-1442 and E-ISSN 2498-6208, it provides a unique local perspective alongside valuable contributions to the global discourse in neuroscience. Despite earning a Q4 quartile ranking in both Neurology and Clinical Neurology, the journal remains dedicated to publishing high-quality research that contributes to the scientific community's collective knowledge. Its coverage spans significant converged years from 1954 to 1985 and now continues through 2024, reflecting a rich historical foundation. Recognizing the importance of open access, the journal strives to enhance accessibility, albeit currently lacking a formal open-access model. Researchers, professionals, and students in the field will find in Ideggyogyaszati Szemle a resource vital for keeping abreast of emerging trends and findings in neurological science.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.